Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation
What happens to muscle, fat and body mass index between 8 and 18 years of age in children with cystic fibrosis
Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation
Use of Cystic Fibrosis inhaled medication after Elexacaftor/Tezacaftor/Ivacaftor in comparison to before
Understanding the relationship between secondhand smoke exposure and lung function in children with cystic fibrosis
